Dyax Corp. (Nasdaq: DYAZ) on Monday announced it will withdraw a marketing authorization application to sell its Kalbitor drug in Europe. Data on the drug, a treatment for the rare disease hereditary angioedema, was deemed insufficient to demonstrate a positive benefit-risk balance, Dyax said in a news release.

SOURCE